Everything Dr. Rick Klausner said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Klausner: Next breakthrough will be curative T-cell therapy for solid tumors
“So I think the next big breakthrough in, in curative therapy is going to be curative therapy for any solid tumor by getting these T cells to have the properties that allow them to stay active even in solid tumors, which have the ability, maybe why they exist, …”
Klausner: Upcoming Patient Trials Could Signal Beginning of End of Cancer
“It's going to be tried in patients over the next year or so. If we were right scientifically, I think we can be thinking about seeing the beginning of the end of cancer.”
Klausner: The National Cancer Institute could not have created GRAIL
“And he asked me explicitly, could you have done that if you were still running the National Cancer Institute? And I believe the answer is no. It's extremely hard to aggregate all of those resources and to create the type of completely mission-driven venture.”
Klausner: Cellular Rejuvenation Would Be Humanity's Biggest Medical Revolution
“Cells are able to do that and the ability to imagine understanding and controlling that would be the biggest revolution in medicine, health, maybe even society that humanity has ever experienced.”
Klausner: Scientists Can Reset Cell Age Without Losing Identity
“Over the last few years, a number of scientists have figured out amazingly how to manipulate the Yamanaka factors to dissociate the resetting of the age clock
From the loss of cell identity.”
Klausner: Rejuvenated Cells Reset to Ages 12 to 20
“The early studies actually suggest that when you rejuvenate cells this way,
They sort of go back to the end of development, sort of the, you know, around 15, you know, 12 to 20, somewhere between puberty and the end of development, and there seems to be a litt…”
Klausner: Cells Can Be Rejuvenated in Days, Enabling Rapid Trials
“We can rejuvenate cells in a couple of days, and as we learn to measure what this, quote, young, healthy cell looks like. It's not about having to ask whether people don't age as much over four decades. It's about the types of measurements that we can do with …”
Klausner: CAR T therapies from Juno and Kite cure end-stage blood cancers
“Over the last five years, through a number of companies in particular, such as Juno, Kite, Novartis, there are now drugs on the market that are curing people with end stage incurable Hematologic malignancies like lymphoma, leukemia, myeloma, with this now one-…”
Klausner: Government must fund basic science while business translates it
“I think the right role for government in this sort of science is to support very undifferentiated basic science. That's the, that sort of is the foundation for now the ability to create Entities that are really good at taking that and turning them into medicin…”
Klausner: FDA engaged quickly and helped biotech startups with cell therapy
“I mean, with companies that I've started, we engage the FDA very quickly. They're interested in the science and they, you know, like with cell therapy, they were incredibly helpful.”
Klausner: Life sciences will drive the 21st century across all industries
“We're at what I think will be viewed as truly a revolutionary golden age in life sciences, which is going to have impacts on everything. Not only we think about it as health, but it's going to change how we think about manufacturing the environment chemistry. …”
Klausner: DNA manipulation and AI convergence are biology's key breakthroughs
“I think the most important breakthroughs has been the ability to read and write DNA. The new ability to actually manipulate and edit DNA. And then I think the convergence of tech and computational sciences and artificial intelligence, machine learning with bio…”
Klausner: Living cell therapies represent the third phase of scientific medicine
“I think we're at the very beginning of the third, maybe even final phase, of scientific therapies, Which are living cells as drugs.”
Klausner: Juno Engineered CAR T Therapies Administered to Outpatients
“With Juno, we were able to make these CAR T cells where almost everyone is treated as an outpatient. They don't even have to go into the hospital.”
Klausner: GRAIL required $1.5B+ in private capital over four years
“And turns out we learned over about four years with over a billion and a half dollars of private investment to figure that out.”
Klausner: Cellular Rejuvenation Will Face Dangers Like Early Gene Therapy
“Actually it's going to be, you know, like with early gene therapy, there'll be surprising dangers and pitfalls. It's all about understanding how do you think about the deep scientific questions and investing in that.”
Klausner: GRAIL clinical trials enrolled over 150,000 participants
“For GRAIL, we had clinical trials that involved over a 150,000 participants, and those are really expensive.”